908 DEVICES INC (MASS)
Sector: Information Technology
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Information Technology
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MASS
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MASS | Director | 62 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RGEN | Director Nominee; Director and Executive Chair of the Board; Executive Chair of the Board and Former Chief Executive Officer | 61 | ["Public Company Board/CEO", "Risk Oversight", "Finance & Capital Markets", "Manufacturing & Global Operations", "Strategic Planning and M&A", "Life Sciences Technology & Innovation", "Commercial Sales & Marketing", "B.S. in Microbiology", "M.S. in Biotechnology", "M.B.A. from Boston University School of Management", "deep understanding of the bioprocessing market", "previously served as President and CEO of Repligen", "experience at Life Technologies Corporation", "experience at Applied Biosystems"] | [] | 2025 |
Biography sourced from the proxy statement filing.
Tony J. Hunt has served as a member of our board of directors since March 2022. Mr. Hunt was the Executive Chairman of the board of directors of Repligen, a publicly traded bioprocessing-focused life sciences company, from September 2024 through March 2026. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations and was named President and CEO in May 2015. Prior to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company, which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the pharmaceutical analytics business that in 2008 became a part of the bioproduction platform at Life Technologies. Mr. Hunt currently serves on the board of directors of BioLife Solutions, Inc. (NASDAQ: BLFS), a developer and supplier of bioproduction tools and services for the cell and gene therapy market, and Ori Biotech, a private company developing next generation cell and gene therapy manufacturing technology. Mr. Hunt holds a B.S. in microbiology and an M.S. in biotechnology from University College in Galway, Ireland, and an MBA from Boston University School of Management. Our board of directors has concluded that Mr. Hunt is qualified to serve as a director because of his deep understanding of the markets we serve.